University of Kentucky

UKnowledge
Radiation Medicine Faculty Publications

Radiation Medicine

2-7-2022

Feasibility of Using Ring-Mounted Halcyon Linac for SingleIsocenter/Two-Lesion Lung Stereotactic Body Radiation Therapy
Damodar Pokhrel
University of Kentucky, damodar.pokhrel@uky.edu

Aaron Webster
University of Kentucky, Aaron.Webster@uky.edu

Richard Mallory
University of Kentucky, Richard.Mallory@uky.edu

Justin Visak
University of Kentucky, justinvisak18@gmail.com

Mark E. Bernard
University of Kentucky, Mark.Bernard@uky.edu

See next page for additional authors
Follow this and additional works at: https://uknowledge.uky.edu/radmed_facpub
Part of the Radiation Medicine Commons

Right click to open a feedback form in a new tab to let us know how this document benefits you.
Repository Citation
Pokhrel, Damodar; Webster, Aaron; Mallory, Richard; Visak, Justin; Bernard, Mark E.; McGarry, Ronald C.;
and Kudrimoti, Mahesh, "Feasibility of Using Ring-Mounted Halcyon Linac for Single-Isocenter/TwoLesion Lung Stereotactic Body Radiation Therapy" (2022). Radiation Medicine Faculty Publications. 33.
https://uknowledge.uky.edu/radmed_facpub/33

This Article is brought to you for free and open access by the Radiation Medicine at UKnowledge. It has been
accepted for inclusion in Radiation Medicine Faculty Publications by an authorized administrator of UKnowledge.
For more information, please contact UKnowledge@lsv.uky.edu.

Feasibility of Using Ring-Mounted Halcyon Linac for Single-Isocenter/Two-Lesion
Lung Stereotactic Body Radiation Therapy
Digital Object Identifier (DOI)
https://doi.org/10.1002/acm2.13555

Notes/Citation Information
Published in Journal of Applied Clinical Medical Physics, e13555.
© 2022 The Authors
This is an open access article under the terms of the Creative Commons Attribution License, which
permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Authors
Damodar Pokhrel, Aaron Webster, Richard Mallory, Justin Visak, Mark E. Bernard, Ronald C. McGarry, and
Mahesh Kudrimoti

This article is available at UKnowledge: https://uknowledge.uky.edu/radmed_facpub/33

Received: 13 May 2021

Revised: 14 January 2022

Accepted: 26 January 2022

DOI: 10.1002/acm2.13555

R A D I AT I O N O N C O L O G Y P H Y S I C S

Feasibility of using ring-mounted Halcyon Linac for
single-isocenter/two-lesion lung stereotactic body
radiation therapy
Damodar Pokhrel
Mark E. Bernard

Aaron Webster
Richard Mallory
Justin Visak
Ronald C. McGarry
Mahesh Kudrimoti

Medical Physics Graduate Program,
Department of Radiation Medicine, University
of Kentucky, Lexington, Kentucky, USA
Correspondence
Damodar Pokhrel, Medical Physics Graduate
Program, Department of Radiation Medicine,
University of Kentucky, Lexington, KY 40509,
USA.
Email: damodar.pokhrel@uky.edu

Abstract
Purpose: To demonstrate the plan quality and delivery efficiency of volumetricmodulated arc therapy (VMAT) with the Halcyon Linac ring delivery system
(RDS) in the treatment of single-isocenter/two-lesion lung stereotactic body
radiation therapy (SBRT).
Materials/methods: Sixteen previously treated non-coplanar VMAT singleisocenter/two-lesion lung SBRT plans delivered with SBRT-dedicated C-arm
TrueBeam Linac were selected. Prescribed dose was 50 Gy to each lesion over
five fractions with treatment delivery every other day and AcurosXB algorithm as
the final dose calculation algorithm.TrueBeam single-isocenter plans were reoptimized for Halcyon Linac with coplanar geometry. Both TrueBeam and Halcyon
plans were normalized for identical combined target coverage and evaluated.
Conformity indices (CIs), heterogeneity index (HI), gradient index (GI), gradient
distance (GD), and D2cm were compared. The normal lung V5Gy, V10Gy, V20Gy,
mean lung dose (MLD), and dose to organs at risk (OAR) were evaluated. Treatment delivery parameters, including beam-on time, were recorded.
Results: Halcyon plans were statistically similar to clinically delivered TrueBeam plans. No statistical differences in target conformity, dose heterogeneity,
or intermediate-dose spillage were observed (all, p > 0.05). Halcyon plans, on
average,demonstrated statistically insignificant reduced maximum dose to most
adjacent OAR and normal lung. However, Halcyon yielded statistically significant
lower maximal dose to the ribs (p = 0.041) and heart (p = 0.026), dose to 1 cc
of ribs (p = 0.035) and dose to 5 cc of esophagus (p = 0.043). Plan complexity
slightly increased as seen in the average increase of total monitor units, modulation factor, and beam-on time by 480, 0.48, and 2.78 min, respectively. However,
the estimated overall treatment time was reduced by 2.22 min,on average.Mean
dose delivery accuracy of clinical TrueBeam plans and the corresponding Halcyon plans was 98.9 ± 0.85% (range: 98.1%–100%) and 98.45 ± 0.99% (range:
97.9%–100%), respectively, demonstrating similar treatment delivery accuracy.
Conclusion: SBRT treatment of synchronous lung lesions via single-isocenter
VMAT on Halcyon RDS is feasible and dosimetrically equivalent to clinically
delivered TrueBeam plans. Halcyon provides excellent plan quality and shorter
overall treatment time that may improve patient compliance, reduce intrafraction
movement, improve clinic efficiency, and potentially offering lung SBRT treatments for underserved patients on a Halcyon only clinic.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided
the original work is properly cited.
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1

INTRODUCTION

Lung cancer is the leading cause of cancer-related mortality in North America with an increasing number of
patients presenting with stage I/II non-small-cell lung
cancer (NSCLC).1 In many cases, these pulmonary cancer patients present with comorbidities that preclude
surgical resection.2,3 For these patients, stereotactic
body radiation therapy (SBRT) is the standard-of -care
due to its extremely effective 3-year local control rates of
up to 97% in the treatment of solitary lung lesions when
compared to conventional lung radiotherapy.4 SBRT is
well-tolerated compared to surgery due to its low rates
of treatment induced toxicity.5–8 Additionally, for the large
and growing cohort presenting with multiple primary
lung tumors or oligometastatic disease, several studies have shown SBRT to be a safe and effective treatment, including phase I/II trials that yielded 1 and 2-year
local control rates of 100% and 96%, respectively.9–11
The effectiveness of lung SBRT depends heavily on the
employed delivery technique and its ability to provide
increased target conformity and rapid dose fall while
accounting for tumor motion due to respiration.12,13
Successful management of these challenging patient
cases requires rapid high-dose fall-off in order to spare
adjacent dose limiting organs and normal lung tissue. This can be especially difficult for pulmonary distressed patients with multiple lung lesions as SBRT
approaches frequently require long treatment times that
can reduce patient compliance and increase intrafraction motion.14–16
Stereotactic treatment of multiple lung lesions can
be delivered asynchronously by using a multi-isocentric
approach, often at the cost of significant increases in
treatment planning, patient set up and treatment delivery time. Alternatively, a single-isocenter technique can
be utilized to treat multiple lung lesions synchronously.
While the latter method can provide substantially shorter
treatments, the effectiveness relies primarily on the
accuracy of patient set up and the precision of treatment
delivery accentuates errors based on various geometric factors.17 Recently, Varian RapidArc® planning with
volume-modulated arc therapy (VMAT) (Varian Medical Systems, Palo Alto, CA, USA) has emerged as an
effective treatment planning and delivery technique in
lung SBRT. This advanced treatment offers higher precision treatments with steep dose gradients, increased
sparing of organs at risk (OAR) and faster delivery times when compared to previous techniques.18,19
Introduction of flattening-filter-free (FFF) beams in
VMAT has further enhanced these capabilities with
higher dose rates, less out of target dose, and reduced

head contamination including improving target dose
coverage at lung–tissue interface compared to flattened beams.20 Moreover, these benefits may be
enhanced for the synchronous treatment of multiple
lung lesions when coupled with an advanced Linac
design.
Recently, Varian Medical Systems introduced a new
jawless, single energy, ring-mounted delivery system,
the Halcyon (V2.0) medical linear accelerator (ring delivery system, RDS).21 The novel system offers a gantry
rotation speed up to 4 revolution/min and is equipped
with a 6MV-FFF beam with a maximum output rate of
800 monitor units (MU)/min. The Halcyon output rate
is substantially lower than that of the 6MV-FFF beam
on C-arm TrueBeam Linac of 1400 MU/min. Halcyon
Linac’s mean energy and nominal depth of maximum
dose is 1.3 MeV and 1.3 cm, whereas the TrueBeam
Linac’s 6MV-FFF yields 1.4 MeV and 1.5 cm, respectively. In contrast to TrueBeam’s single layer Millennium
120 MLC design, Halcyon RDS is equipped with a duallayer stacked and staggered MLC design (SX2) that,
like the Millennium 120, offers an effective resolution
of 5 mm MLC width at the treatment isocenter. Halcyon
has a field size restriction of 28 × 28 cm2 , but due to the
novel MLC design, can achieve full leaf interdigitation
with a maximal leaf travel of 28 cm. Halcyon also boasts
a reduced beam penumbra as seen in the smaller dosimetric leaf gap of 0.1 mm due to its improved focused
tip design. Moreover, the SX2 has a faster leaf acceleration and velocity (200 cm/s/s and up to 5 cm/s,
respectively) at the plane of isocenter compared to the
Millennium 120 MLC (50 cm/s/s and 2.5 cm/s, respectively). The unique stacked design allows for ultra-low
leakage and transmission of roughly 0.4% which may
improve treatment accuracy.22,23 Additionally, Halcyon
comes equipped with fast on-board imaging capable
of up to 15-s kilovoltage cone beam computed tomography (kV-CBCT) imaging with an advanced iterative
CBCT (iCBCT) reconstruction algorithm.24 Halcyon
also reduces patient set up time significantly with the
convenience of a fully automated one-step patient set
up approach where isocenter shifts are automatically
applied.21
In the stereotactic treatment regime, there have
been limited studies that demonstrate the feasibility of
using Halcyon RDS for the treatment of both intracranial and extracranial disease.25–29 In a planning study
comparing TrueBeam and Halcyon, Petroccia et al.27
concluded that clinically acceptable spine SBRT is possible with Halcyon RDS. In the clinical setting, Pokhrel
et al.28,30 reported successful clinical implementation
of Halcyon in the delivery of prostate and single lung
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Main tumor characteristics of the 16 lung stereotactic body radiation therapy (SBRT) patients included in this study
Mean ± SD (range or n: no.
of patients)

Parameters
Tumor 1, PTV1 (cc)

25.9 ± 23.4 (4.9–81.2)

Tumor 2, PTV2 (cc)

20.8 ± 12.9 (6.4–41.0)

Tumor location (left/right/bilateral lungs)

n = 5/3/8

Distance to isocenter (cm)

5.5 ± 2.5 (2.4−10.2)

Normal lung volume (cc)

3526.0 ± 1180.0 (1892.0−6542.0)

Note: Each patient had two tumors. Dose was 50 Gy in five fractions to each tumor.
Abbreviations: PTV, planning target volume; SD, standard deviation.

lesion SBRT treatments. In the single-isocenter/multilesion setting, Li et al.29 conducted a retrospective planning study that demonstrated Halcyon 2.0 to be capable
of generating similar plan quality to C-arm TrueBeam
in the treatment of six to 10 brain lesions with a singleisocenter VMAT approach. Although these studies show
promise for increasing Halcyon’s role in the SBRT treatment delivery, there is currently no literature addressing the feasibility of using Halcyon RDS in the treatment of multiple lung lesions with SBRT. In this study, we
conduct a retrospective evaluation of plan quality and
delivery efficiency using a ring-mounted Halcyon Linac
in the delivery of single-isocenter/two-lesion VMAT lung
SBRT for 16 patients previously treated on a TrueBeam
Linac. We also assess clinical acceptability by evaluating adherence to RTOG-0813/NRG-BR001 lung SBRT
protocol requirements.3,11

2

1.0 cm expansion of the GTV in the superior–inferior
direction and a 0.5 cm expansion laterally.3 For patients
not able to tolerate abdominal compression, in addition
to free-breathing 3D-CT, 4D-CT scans were obtained
using the Varian RPM system (version 1.7). Maximum
intensity projection (MIP) images were then created and
co-registered to free-breathing 3D-CT scans to facilitate internal target volume (ITV) delineation. PTV were
then defined by a 0.5 cm expansion of the ITV. All
treatment planning was performed on the free-breathing
3D-CT dataset. As per the requirements established in
RTOG-0813, all relevant critical OARs were delineated
to include spinal cord, heart/pericardium, bronchus,
trachea, esophagus, skin, ribs (right, left, and combined), and normal uninvolved lung (right, left, combined). Table 1 summarizes the lesion characteristics
and geometries for all 16 lung SBRT patients used in this
study.

MATERIALS AND METHODS

Upon attaining Institutional Review Board approval, a
total of 16 patients with stage I–II NSCLC metastatic
lesions previously treated to 50 Gy in five fractions with single-isocenter/two-lesion lung SBRT on a
TrueBeam Linac were selected for this retrospective
study.

2.1
Patient set up and target
delineation
Patient immobilization was achieved using the Body
Pro-Lok™ platform (CIVCO system, Orange City, IA,
USA).All patients were placed in the supine position with
their arms over their head and if possible, diaphragmatic
compression was utilized to reduce motion to no more
than 1.0 cm. Simulation was conducted using a freebreathing 3D-CT scan with GE Lightspeed 16 slice CT
scanner (General Electric Medical Systems, Waukesha,
WI, USA) in helical mode. Gross target volumes (GTV)
were delineated based on observable tumor mass followed by creation of planning target volumes (PTV) via

2.2
2.2.1

Treatment planning
Clinical TrueBeam VMAT plans

All patients were treated with a highly conformal VMAT
plan using two to four non-coplanar (±5◦ –10◦ couch
rotations) or coplanar partial/full arcs on a TrueBeam
Linac equipped with a Millennium 120 MLC using the
6MV-FFF beam with a maximum output rate setting
of 1400 MU/min. Due to clearance issue, four patient’s
plans consisted entirely of coplanar beam geometry.The
TrueBeam couch top and the SBRT board were inserted
as planning structures. A single-isocenter was placed
approximately equidistant between the two lesions. As
the isocenter does not always need to be precisely
between the lesions, an offset was applied to facilitate
gantry rotation for the partial arcs. Collimator angles
for these arcs were chosen to minimize tongue and
groove multileaf collimators (MLC) leakage and dose
bridging throughout gantry rotation. Jaw tracking option
was also used to reduce leakage dose outside the field.
The isocenter to tumor distance was the 3D linear distance from the placement of the single isocenter to the
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geometric center of each lesion. A dose of 50 Gy in five
fractions was prescribed to the 70%–80% isodose line
and normalized such that 95% of each PTV received
100% of the prescription dose with a target maximum
GTV dose of 120%–130%. Clinical plans were generated using the Eclipse TPS inverse optimizer (Photon
Optimizer, PO version 13.6 or 15.6) with final dose
calculation using the AcurosXB algorithm with 1.25 mm
dose calculation grid size (CGS), tissue heterogeneity
corrections,31,32 and dose to medium reporting mode
enabled. Planning objectives were established using
NRG-BR001 or RTOG-0813 guidelines.3,11 Patients
were treated every other day per lung SBRT protocol, and an online pre-treatment CBCT scan was
performed prior to each treatment for patient set up
corrections.

2.2.2

Halcyon VMAT plans

For comparison, all TrueBeam single-isocenter plans
were reoptimized for Halcyon RDS coplanar geometry
with two to four partial/full arcs using 6MV-FFF beam
and a maximum output rate of 800 MU/min. The TrueBeam couch structure was replaced by the Halcyon
couch model and the SBRT board was used as before.
Dose calculation algorithm, CGS, convergence mode,
and PO settings were identical to TrueBeam plans. However, jaw tracking was not available due to the jawless design of Halcyon RDS. All Halcyon plans were
normalized to achieve identical combined target coverage to clinical TrueBeam plans providing similar target
maximum dose.

2.3

Plan evaluation

Both TrueBeam and Halcyon plans were evaluated
using NRG-BR001 and RTOG-0813 SBRT protocol
requirements for target coverage and dose to OAR. For
each lesion, target conformity index (CI) and Paddick
conformation number (PCN)33 were determined using
the ratio of the prescription isodose volume to the PTV
and the ratio of the target volume covered by the prescription isodose squared to the product of the target
volume and prescription isodose volume, respectively.
The heterogeneity index (HI), used to evaluate plan
hot spots, is the ratio of target maximum dose (Dmax )
to the prescribed dose and the gradient index (GI) is
the ratio of the 50% prescription isodose volume to the
target volume. Additionally, intermediate-dose fall-off
was assessed using maximum dose to any point 2 cm
away from the target margin (D2cm ) and recorded as
percent of the prescription dose. As per RTOG requirements, percentage of normal lung receiving V20Gy was
assessed along with the additional metrics of V5Gy,

V10Gy, and mean lung dose (MLD). In addition to normal lung doses, maximal and volumetric dose to spinal
cord, heart, esophagus, trachea/bronchial tree, ribs, and
skin were evaluated per RTOG-0813 and NRG-BR001
guidelines. All dosimetric parameters where then compared between clinical TrueBeam plans and the fully
reoptimized Halcyon plans.

2.4
Treatment delivery efficiency
and accuracy
For each plan, delivery efficiency was assessed by
evaluating the total number of MU per fraction and the
beam modulation factor (MF) defined as the ratio of
total number of MU to the fractional prescription dose
in cGy. The actual beam-on time was determined by
dividing the total MU by the dose rate of 1400 MU/min
for TrueBeam plans and 800 MU/min for Halcyon plans
as observed on each plan. For a total of 50 Gy in five
fractions prescription, each plan achieved the corresponding maximal dose rates for each control point
for both machines. Total treatment time for TrueBeam
plans incorporated: patient set up, 1-min pre-treatment
CBCT, manual image matching, shift application, and
beam-on time; manual couch rotations during treatment
for non-coplanar arcs were not included in this estimate. For Halcyon RDS, total treatment time included:
patient “one-step set up”, 15-s pre-treatment kV-iCBCT,
automatic image matching and shift application, and
beam-on time. Delivery accuracy was evaluated by
performing pre-treatment portal dosimetry (PD) quality
assurance (QA) measurements on the Linac used for
each plan with a gamma evaluation criteria of 2%/2 mm
and low-dose threshold set to 5%.34,35 The electronic
portal imaging device (EPID, aS1200 flat panel detector;
Varian Medical Systems) mounted on each machine
includes a detector area of 40 cm × 40 cm providing
a resolution of 0.34 mm was used for PD QA measurements. Additionally, overall treatment delivery time
was estimated by incorporating the patient set up,
CBCT imaging and registration, and patient set up verification times for each delivery platform as described
above.

2.5

Data analysis

To assess the normality of each parameter, the Shapiro
test followed by an evaluation of skewness and kurtosis was conducted. Comparison of dosimetric parameters and metrics was performed using the Wilcoxon
rank test (nonparametric) or paired samples t-test
(parametric) and a significance level of p-value of <0.05
in SPSS 27 data analysis software (IBM, New York, NY
USA).
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TA B L E 2 Analysis of the target metrics for all 16 lung stereotactic body radiation therapy (SBRT) patients treated with
single-isocenter/multiple-lesions volumetric-modulated arc therapy (VMAT) plans on TrueBeam compared to Halcyon
Target

Parameter

PTV(n = 32)

GTV
(n = 32)

TrueBeam VMAT

Halcyon VMAT

p-Value

% Volume covered by Rx dose (%)

96.6 ± 1.5 (95.1−99.6)

96.4 ± 1.3 (95.2–98.8)

0.476

CI

1.06 ± 0.1 (0.89−1.29)

1.04 ± 0.09 (0.93−1.21)

0.054

PCN

0.89 ± 0.06 (0.76−0.96)

0.91 ± 0.04 (0.77−0.96)

0.649

HI

1.24 ± 0.05 (1.15−1.27)

1.22 ± 0.05 (1.14−1.31)

0.091

GI

5.25 ± 1.06 (3.60−7.64)

5.13 ± 1.13 (3.69−8.12)

0.136

D2cm (%)

54.8 ± 5.9 (47.6−68.9)

54.1 ± 4.3 (47.2−65.8)

0.869

Minimum dose (Gy)

53.8 ± 2.9 (46.5−58.4)

53.5 ± 2.1 (50.4−58.0)

0.698

Maximum dose (Gy)

61.1 ± 1.4 (57.5−63.5)

60.3 ± 2.2 (57.0−65.5)

0.114

Mean dose (Gy)

57.1 ± 1.3 (54.9−60.8)

57.4 ± 1.8 (54.2−60.5)

0.122

Note: Mean ± SD (range) and p-values were reported.
Abbreviations: CI, conformity index; GI, gradient index; GTV, gross tumor volume; HI, heterogeneity index; PCN, Paddick conformation number; PTV, planning target
volume; SD, standard deviation.

TA B L E 3 Normal lung dose statistics between single-isocenter TrueBeam volumetric-modulated arc therapy (VMAT) and Halcyon VMAT
plans for all 16 lung stereotactic body radiation therapy (SBRT) patients with two tumors
Plan type

V20Gy (%)

V10Gy (%)

V5Gy (%)

MLD (Gy)

TrueBeam VMAT

8.8 ± 4.8 (2.7−14.9)

23.0 ± 11.7 (7.8−43.4)

34.3 ± 14.6 (11.6−56.3)

6.5 ± 2.8 (2.4−10.9)

Halcyon VMAT

8.5 ± 4.7 (2.5−15.2)

21.9 ± 11.1 (8.2−37.6)

34.5 ± 14.7 (12.4−56.6)

6.4 ± 2.6 (2.4−9.8)

p-Value

0.387

0.145

0.942

0.466

Note: Mean ± SD (range) and p-values were reported.
Abbreviations: MLD, mean lung dose; SD, standard deviation.

3

RESULTS

Target coverage and
3.1
intermediate-dose spillage
Plan quality and target metrics are displayed in Table 2
for both TrueBeam and Halcyon plans, each demonstrating compliance with NRG-BR001 protocol requirements. Both plans produced statistically insignificant
differences in target coverage, GTV doses (minimum,
maximum, mean), CI, and PCN demonstrating similar
target coverage can be achieved. Even with Halcyon’s
coplanar geometry, target dose, HI, GI, and D2cm show
slight but statistically insignificant improvements when
compared to clinical TrueBeam plans.

3.2

Dose to normal lung

The dose to normal lung was evaluated using V20Gy as
specified by the RTOG-0813 protocol along with V5Gy,
V10Gy, and MLD. The detail results for both plans are
shown in Table 3. On average, Halcyon plans demonstrated statistically insignificant decreases in all normal
lung metrics compared to clinical TrueBeam plans, for
example, with V10Gy showing the largest reduction of
1.1%.

3.3

Dose to other OARs

As per RTOG-0813/BR001 protocol requirements, maximal and volumetric dose to OAR (cord, heart, esophagus, trachea/bronchus, skin, ribs) were recorded for
both TrueBeam and Halcyon plans. Paired volumetric differences for all OAR with respect to TrueBeam
plans are presented graphically in Figure 1 and tabulated results for volumetric and maximal dose are
shown in Table 4. Positive values indicate that Halcyon plans decreased OAR dose when compared to
the clinical TrueBeam plans. Both plans met all protocol compliance criteria for OAR sparing and were
clinically acceptable. Most comparisons yielded statistically insignificant differences with the exception of an
average dose reduction to 1 cc and maximal dose to
ribs of 0.43 Gy (p = 0.033) and 1.50 Gy (p = 0.041),
respectively. The maximal dose reduction to the heart
of 3.36 Gy (p = 0.025) and dose to 5 cc of esophagus was 0.9 Gy (p = 0.043) in Halcyon plans, respectively. It is also important to note that although not
statistically significant, on average, Halcyon plans provided additional dose reductions of 0.81 Gy to the heart
(15 cc), 1.3 Gy maximal dose to the esophagus, and
0.95 Gy (4 cc) and 0.51 Gy (maximal dose) to the proximal bronchial tree indicating clinically significant dose
reductions.
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Evaluation of dose to organs at risk (OAR) for all 16 two-lesion lung stereotactic body radiation therapy (SBRT) patients for both

Dose to OAR

Parameters

Difference = TrueBeam
minus Halcyon plans

p-Value

Spinal cord (Gy)

Dmax

0.13 ± 2.35 (-2.21 to 5.60)

0.910

D0.35cc

0.33 ± 1.98 (-2.34 to 4.64)

0.956

Dmax

3.36 ± 4.49 (-1.72 to 14.08)

0.026

D15cc

0.81 ± 1.71 (-2.15 to 4.01)

0.063

Dmax

1.30 ± 3.43 (-3.39 to 8.01)

0.275

D5cc

0.89 ± 2.22 (-2.56 to 6.14)

0.043

Dmax

0.51 ± 3.91 (-4.50 to 8.15)

0.681

D4cc

0.95 ± 2.14 (-1.89 to 4.75)

0.136

Dmax

0.18 ± 2.06 (-3.01 to 3.23)

0.733

D10cc

0.17 ± 0.88 (-0.69 to 2.14)

0.286

Dmax

1.50 ± 2.61 (-1.57 to 7.07)

0.041

D1cc

0.43 ± 1.23 (-1.39 to 2.59)

0.033

Heart/pericardium (Gy)

Esophagus (Gy)

Trachea/bronchus (Gy)

Skin (Gy)

Ribs (Gy)

Note: Mean ± SD (range) was reported. Statistically significant p-values are highlighted in bold.
Abbreviation: SD, standard deviation.

F I G U R E 1 Organs at risk (OAR) volumetric dose differences
(TrueBeam minus Halcyon) for all 16 synchronous volumetricmodulated arc therapy (VMAT) lung stereotactic body radiation
therapy (SBRT) patients. Mean difference is the blue box plot with
upper and lower boundaries are the maximum and minimum dose
differences. On average, Halcyon plans yielded dose reductions to all
critical organs including 15 cc of heart, 4 cc of bronchial tree, 5 cc of
esophagus, and a statistically significant decrease in dose to 1 cc of
ribs and 5 cc of esophagus. Dose to 10 cc of skin and 0.35 cc of
spinal cord show minimal change in Halcyon plans due to coplanar
geometry

3.4
Treatment delivery efficiency
and accuracy
Analysis of treatment delivery efficiency was performed
for both TrueBeam and Halcyon plans by comparing the
mean total number of MU and its associated metrics of
beam MF, beam-on time, and overall treatment time (see
Table 5). When compared to clinical TrueBeam plans,
Halcyon plans provided increased total MU on average
by 480 MU (p = 0.041) thus resulting in a corresponding increase in MLC MF of 0.48. On average, beamon time also increased in Halcyon plans by 2.78 min
(p < 0.001) reflecting the effect of lower maximal dose

rate of Halcyon (800 MU/min) when compared to TrueBeam (1400 MU/min). However, mean overall treatment
time did decrease in Halcyon plans by 2.22 min (range,
1.38–3.41 min) due to several factors as mentioned
above. When compared to TrueBeam’s 1-min CBCT
scan times and manual image matching procedure, Halcyon RDS offers a gantry rotation speed up to four times
faster than TrueBeam and a more streamlined fully automated “one-step patient set up” with a high-quality 15-s
kV-iCBCT scanning capability and auto-image matching
feature.
As mentioned previously, treatment delivery accuracy of both Halcyon and clinical TrueBeam plans
was assessed via treatment plan delivery in patientspecific QA measurement mode on both Linacs using
the respective on-board EPID imager followed by evaluation of gamma pass rates by PD. Mean dose delivery accuracy of TrueBeam clinical plans and the corresponding Halcyon plans was 98.9 ± 0.85% (range
98.1%–100%) and 98.5 ± 0.99% (range 97.9%–100%),
respectively, demonstrating a statistically insignificant
decrease in the QA pass rates for Halcyon plans even
with slightly higher beam modulation. Due to the higher
pixel resolution of the aS1200 EPID detector (0.34 mm)
and its limited ability to identify the small dosimetric differences for 3%/3 mm gamma clinical criteria, ≥95%
pass rates with 2%/2 mm gamma criteria was used for
analyzing the data.

3.5

Bilateral lesions example case

An example patient from the cohort representing the typical findings of the study is illustrated in Figures 2 and 3.
This patient had bilateral lung lesions located in the right
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TA B L E 5 Comparison of average values (and range) of treatment delivery parameters between clinical TrueBeam volumetric-modulated
arc therapy (VMAT) and Halcyon plans for all 16 lung stereotactic body radiation therapy (SBRT) patients with two lesions
p-Value

Beam delivery parameters

TrueBeam VMAT plans

Halcyon VMAT plans

Total MU/fraction

4052 ± 702 (2770−5439)

4532 ± 890 (2852−6007)

0.041

Modulation factor

4.05 ± 0.71 (2.77−5.44)

4.53 ± 0.89 (2.85−6.01)

0.043

Beam-on time (min)

2.89 ± 0.50 (1.98−3.89)

5.67 ± 1.11 (3.57−7.51)

<0.001

Treatment time (min)

12.89 ± 0.51 (11.98−13.89)

10.67 ± 1.12 (8.57−12.51)

<0.001

Pre-treatment PD QA pass
rates (%) for (2%/2 mm)

98.9 ± 0.85 (98.1−100)

98.45 ± 0.99 (97.9−100)

0.064

Note: Mean ± SD (range) was reported. Statistically significant p-values are highlighted in bold.
Abbreviations: MU, monitor units; PD, portal dosimetry; QA, quality assurance; SD, standard deviation.

upper lobe (RUL) and left upper lobe (LUL). The combined PTV was 20.5 cc (RUL: 7.3 cc and LUL: 13.2 cc)
with an average distance from isocenter to the center of
the lesion of 5.3 cm. The TrueBeam clinical plan utilized
three partial arcs, two coplanar, and one non-coplanar
(10◦ couch rotation), with an arc length of 150◦ and
three different collimator rotations. For the Halcyon plan,
three coplanar partial arcs were used with an arc length
of 270◦ and three different collimator rotations. For this
patient, TrueBeam yielded a combined CI, HI, GI, D2cm ,
and V20Gy of 1.03, 1.20, 5.6, 50.6%, and 2.7% versus
1.05, 1.24, 5.6, 55.4%, and 2.5% for the Halcyon plan.
All maximal and volumetric doses to OAR were within
RTOG-0813/BR001 compliance criteria. Total MU per

fraction, MF, beam-on time, and treatment time for TrueBeam was 3796, 3.8, 2.71 min, and 12.71 min compared
to Halcyon’s 4608,4.61,5.75 min,and 10.76 min,respectively.Figure 2 shows the dose distributions of both plans
in axial and coronal planes for the example patient. As
is evident by the increase in D2cm , the dose color wash
(Figure 2) shows that the coplanar geometry of Halcyon produces a slight elongation of the 50% isodose
for the lesion in the RUL compared to the non-coplanar
TrueBeam plan. However, as shown by the cumulative
dose volume histogram in Figure 3, the Halcyon plan
is still able to provide clinically significant dose escalation to both GTVs while providing similar or better OAR
sparing.

F I G U R E 2 Axial and coronal plane of an example patient’s clinical plan (right panel) and Halcyon plan (left panel) using a single-isocenter
placed between the lesions. Shown is gross tumor volumes (GTVs) (red), planning target volumes (PTVs) (pink), ribs (green), cord (yellow),
esophagus (green), trachea (orange), bronchus (light green), and normal lung (cyan). Isodose color wash (25–60 Gy) and D2cm ring (purple) to
each tumor shows similar target conformity and intermediate-dose spillage to non-coplanar TrueBeam at minimal cost to plan complexity
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F I G U R E 3 Dose volume histogram for the example patient shown in Figure 2. The patient had bilateral lung lesions that were treated
synchronously. The triangles represent the clinical TrueBeam plan and squares represent Halcyon plan. Structures shown are gross tumor
volumes (GTVs) (red and dark red), planning target volumes (PTVs) (pink and magenta), ribs (green), heart (blue), cord (yellow), esophagus
(orange), trachea (purple), and normal lung (cyan). For this patient, Halcyon plan provided substantial GTV dose escalation to both lesions while
maintaining comparable intermediate/high-dose spillage and similar or better organs at risk (OAR) sparing

4

DISCUSSION

We evaluated the plan quality, delivery efficiency, and
accuracy of VMAT plans via a novel Halcyon RDS in
the treatment of single-isocenter/two-lesion lung SBRT
following RTOG-0813/NRG-BR001 protocol requirements and comparison with clinically delivered noncoplanar/coplanar TrueBeam plans. Comparison with
clinical TrueBeam plans provided a reference for achievable plan quality at our clinic for the highest quality of
patient treatment. Our findings suggest that for select
lung cancer patients, Halcyon RDS is capable of delivering highly conformal single-isocenter/two-lesion lung
SBRT treatments that meet all the RTOG-0813/NRGBR001 compliance criteria and are dosimetrically similar to our SBRT-dedicated TrueBeam Linac in terms of
plan quality and deliverability. Specifically, Halcyon produced no statistical or clinically significant differences
in target metrics at no additional cost to OAR dose sparing. While Halcyon plans required slightly more MU (480,
on average), pre-treatment QA suggest similar plan
deliverability and treatment accuracy can be achieved.
We estimated Halcyon reduced overall treatment time
by 2.22 min on average despite the MU increase
because enhanced built in fully automated patient set up
capabilities permit time saving. As mentioned earlier, this
is due to therapists not having to enter the room to manually apply the shifts or couch rotations as is the case
for non-coplanar VMAT arcs in TrueBeam plans, as well
as avoiding patient collision issue on Halcyon RDS.

In the past years, the efficacy of the single-isocenter
approach to treating multiple lung lesions has been
examined by several studies.15,36–38 In one of the
first studies to evaluate this approach in the lung,
Zhang et al.36 compared intensity modulated radiation
therapy (IMRT) treatments consisting of coplanar and
non-coplanar field geometries with helical tomotherapy in the treatment of multiple lung lesions using
a single-isocenter plan. Although the results showed
improved target coverage and increased dose sparing of adjacent OAR, average treatment time was well
over an hour with increased low-dose volumes that
could present toxicity concerns in normal lung tissue.
More recently, Quan et al.37 reported a study that
contained 11 patients with two or more lesions that
received 30–54 Gy in three to five fractions using the
single-isocenter technique. This study produced highquality clinical VMAT plans and substantial reductions
in treatment time when compared to a traditional multiisocentric approach.Furthermore,Sanford et al.15 implemented a single-isocentric VMAT planning technique
clinically, using TrueBeam Linac and a 6MV-FFF beam
to treat eight patients with two peripherally located
lung lesions with prescription doses of 50–54 Gy in
three to five fractions. They reported similar dosimetric plan quality to two-isocenter plans and significant
reductions in treatment time, however, they did observe
small increases in normal lung V5Gy, V10Gy, and MLD
as the distance between lesions increased. However, in
a clinical follow up results to that study, Pokhrel et al.38
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reported 100% local control rates and no treatmentrelated acute toxicity (mean, 9 months) thus mitigating
the concerns of these slight dose increases.
Halcyon may improve single-isocenter/multiple-lesion
lung SBRT treatment with respect to previous studies
conducted with helical tomotherapy.36,39 In a retrospective planning study conducted by Deng et al.40 that evaluates the performance of Halcyon RDS in the treatment of multiple brain lesions with a single-isocenter
plan, the study compared dynamic conformal arc (DCA)
and TrueBeam HDMLC (2.5 mm leaf) coplanar and
non-coplanar plans with the Halcyon 2.0 VMAT plans.
The Halcyon plan yielded similar conformity, but inferior GI compared to clinical DCA coplanar and noncoplanar plans for lesions larger than 1.0 cm in diameter.
They also observed reduced low-dose spillage for Halcyon plans compared to TrueBeam coplanar and noncoplanar plans. In contrast to our study, it is important
to note that dosimetric characteristics in the brain will
not necessarily translate to the heterogeneities present
in the lung tumors. In some cases, our results do show
slightly inferior D2cm and GI due to the coplanar limitation of Halcyon RDS. However, reduced MLC transmission has been shown to be a dominant factor in
increased OAR sparing in highly modulated plans as
reported by Li et al.,29 that was similar to our study.
Therefore, in addition to faster MLC speed and given
Halcyon’s ultra-low MLC leakage and transmission dose
(∼0.4%) compared to the higher leakage/transmission
of TrueBeam 6MV-FFF beam (1.5%), it is reasonable to
conclude that for some treatment geometries, Halcyon
RDS should be capable of similar or better normal tissue sparing despite the increased degree of modulation
observed in this study.
Although this study shows promise for future treatments of single-isocenter/two-lesion VMAT lung SBRT
on Halcyon RDS, it does have some limitations. Most
importantly, Halcyon currently is unable to apply rotational corrections to the treatment couch position, limiting patient set up verification to only three translational
corrections. Our TrueBeam however, is equipped with a
perfect-pitch couch allowing both rotational and translational corrections to patient set up in treatments of synchronous lung lesions.The dosimetric impact of this limitation is not currently known for Halcyon RDS and is currently under investigation. Another limitation observed
in this study is that Halcyon’s maximum achievable
dose rate of 800 MU/min is substantially lower than
TrueBeam’s maximum dose rate of up to 1400 MU/min
when using 6MV-FFF beam. Although in this study we
observed the maximum dose rate throughout all the
control points in the TrueBeam treatment delivery, the
slower gantry rotation speed can decrease the treatment time throughout the treatment whereas Halcyon
is able to maintain delivery at the maximum dose rate
and up to four times faster the gantry rotation speed. An
upgrade of Halcyon’s maximal achievable dose rate of

9 of 11

up to 1000 MU/min could potentially result in beam-on
times much closer or even faster to that of current
TrueBeam delivery and further reduce overall treatment
times.
In summary, we have demonstrated that use of Halcyon RDS for VMAT to deliver synchronous SBRT treatment to two lung lesions using a single-isocenter plan is
not only feasible but can potentially be advantageous for
select lung cancer patients who may not tolerate traditional longer SBRT treatment times due to back pain,
distress and discomfort, or shortness of breath. Halcyon’s enhanced MLC design along with ultra-low leaf
transmission/leakage and increased travel speeds result
in similar target coverage, intermediate- and high-dose
spill, and similar or better dose to adjacent OAR. Moreover, Halcyon RDS requires minimal patient set up time
when compared to TrueBeam and is capable of gantry
rotation speeds of up to 4 revolutions/min resulting in a
clinically significant reduction in overall treatment time,
potentially improving patient comfort and clinic workflow.
This benefit could potentially reduce intrafraction motion
and the resulting dosimetric error,which has been shown
to increase linearly with treatment time.14 Based on this
research and our previous studies, we plan on continuing our efforts to define the capabilities and limitations of
Halcyon RDS by quantifying the dosimetric impact due
to the lack of rotational corrections as well as the detail
effects of the dual-layer MLC in the future investigations.

5

CONCLUSION

This study has demonstrated the efficacy of singleisocenter/two-lesion VMAT lung SBRT delivery on the
Halcyon RDS for the select lung cancer patients. The
results indicate that Halcyon can provide safe, effective,
and accurate treatments that are dosimetrically equivalent or potentially preferable when compared to SBRTdedicated TrueBeam plans with minimal or no additional cost in plan complexity and dose to OAR. For
clinics equipped only with Halcyon, this could provide
an additional treatment capability for the patient cohort
located in underserved areas and unable to travel to
larger treatment centers due to physical or financial limitations. Conversely, busy treatment centers with Halcyon RDS, currently employing C-arm Linacs for this
technique, could provide an additional platform for lung
SBRT treatment delivery. Additionally, for select lung
cancer patients who may not tolerate longer treatment
times due to back pain, shortness of breath, and discomfort, Halcyon’s highly automated patient set up coupled with faster gantry speed offers a reduction in overall
treatment time, potentially reducing dosimetric error due
to intrafraction patient motion. However, for two-lesion
lung SBRT patients, further investigation should be conducted to determine the dosimetric impacts of Halcyon’s
inability to correct rotational patient set up error.
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